The 2026 European Society of Urology Annual Meeting released the weighty data, and Johnson and Johnson developed the Erda iDRS Phase I clinical results of the Erda iDRS intravesical sustained-release drug delivery system. For medium and high risk non muscle invasive bladder cancer with FGFR gene mutation, this local drug delivery scheme has achieved complete and lasting tumor relief, which is expected to become the first FGFR targeted therapy for early bladder cancer, and solve the clinical problem of recurrent early bladder cancer.
Traditional oral edatinib has been approved in China for the treatment of advanced urothelial carcinoma after immunotherapy failure. However, oral administration will lead to systemic drug exposure, hyperphosphatemia, stomatitis and other adverse reactions, limiting its long-term use in early bladder cancer. The all-new Erda iDRS is a bladder local sustained-release formulation of Erdaptinib, which is directly infused into the bladder lesion site and continuously releases Erdaptinib at the tumor site. The drug concentration in the lesion is significantly increased, while the amount of drug entering the bloodstream is significantly reduced, and systemic side effects are significantly reduced.
This phase one clinical study has achieved the predetermined primary safety endpoint. In the patients with recurrent moderate risk non muscle invasive bladder cancer, the local preparation of erdatinib achieved a high complete remission rate and a prominent remission duration; The high-risk population also observed ideal recurrence free benefits. FGFR gene variation accounts for a high proportion in early bladder cancer population, about 70% of medium risk and 40% of high-risk non muscle invasive bladder cancer have FGFR related gene changes, which also means that the local dosage form of erdatinib has a large group of applicable patients.
At present, the project has advanced to the second and third phase clinical trial stages. For a long time, the postoperative recurrence rate of non muscle invasive bladder cancer remains high, and the current choice of bladder perfusion drugs is limited, so many patients need repeated operations. If the local sustained-release dosage form of eldatinib successfully completes the follow-up clinical work, it will rewrite the treatment pattern of early bladder cancer and provide a new targeted perfusion scheme for patients with FGFR mutations.
Experts in the industry said that the oral preparation of Erdatinib has proved the value of FGFR targeted drugs in advanced bladder cancer. The clinical data of the Erdatinib bladder sustained-release preparation expanded the FGFR targeted treatment from advanced urothelial cancer to early bladder cancer, and achieved a significant extension of the Erdatinib indication scenario, which is a hot progress in the field of precision treatment of bladder cancer this year.
FAQ
1: What is Erda-iDRS?
It is an intravesical sustained-release delivery system for erdafitinib, designed for local bladder instillation.
Q2: What are the advantages compared to oral erdafitinib?
Local administration results in higher drug concentrations at the lesion site and fewer systemic adverse reactions.
Q3: Which patients are the target population?
Patients with intermediate- to high-risk non-muscle-invasive bladder cancer (NMIBC) harboring FGFR gene alterations.
Conclusion
The clinical results of the new erdafitinib formulation further solidify the role of the FGFR pathway in the precision treatment of bladder cancer. As further clinical trials progress, erdafitinib holds the potential to establish a comprehensive targeted therapy continuum spanning the entire spectrum of bladder cancer-from early to advanced stages-thereby offering a wider range of treatment options to patients.
